FR4474M - - Google Patents

Info

Publication number
FR4474M
FR4474M FR995768A FR995768A FR4474M FR 4474 M FR4474 M FR 4474M FR 995768 A FR995768 A FR 995768A FR 995768 A FR995768 A FR 995768A FR 4474 M FR4474 M FR 4474M
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR995768A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR4474M publication Critical patent/FR4474M/fr
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
FR995768A 1963-11-26 1964-11-20 Expired FR4474M (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32623663A 1963-11-26 1963-11-26

Publications (1)

Publication Number Publication Date
FR4474M true FR4474M (fr) 1966-10-03

Family

ID=23271389

Family Applications (1)

Application Number Title Priority Date Filing Date
FR995768A Expired FR4474M (fr) 1963-11-26 1964-11-20

Country Status (4)

Country Link
BE (1) BE655985A (fr)
BR (1) BR6464291D0 (fr)
FR (1) FR4474M (fr)
GB (1) GB1025578A (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191828A (en) * 1976-04-14 1980-03-04 Richardson-Merrell Inc. Process for preparing 2-(2,2-dicyclohexylethyl)piperidine
GEP20074134B (en) 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (fr) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil dans des thérapies combinées pour le traitement de l'hypertension artérielle pulmonaire
EP2111863B1 (fr) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Combinaison du fasudil et bosentan pour le traitement de l'hypertension artérielle pulmonaire
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
WO2012037665A1 (fr) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Oxyde nitrique libérant un ester d'acide aminé pour le traitement de l'hypertension pulmonaire et autres états respiratoires
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
BR6464291D0 (pt) 1973-07-26
GB1025578A (en) 1966-04-14
BE655985A (fr) 1965-05-19

Similar Documents

Publication Publication Date Title
AR142945A1 (fr)
FR4474M (fr)
AT260747B (fr)
BE616830A (fr)
BE31062A (fr)
BE625828A (fr)
BE462764A (fr)
BE465565A (fr)
BE507458A (fr)
BE533484A (fr)
BE547422A (fr)
BE571209A (fr)
BE625880A (fr)
BE645742A (fr)
BE645320A (fr)
BE644970A (fr)
BE644471A (fr)
BE644304A (fr)
BE582314A (fr)
BE603935A (fr)
BE608372A (fr)
BE643968A (fr)
BE612803A (fr)
BE643506A (fr)
BE643501A (fr)